GM1神經節苷脂沉積症治療市場：依產品類型、疾病類型和地區分類

GM1 Gangliosidosis Treatment Market, By Product Type, By Disease Type, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

GM1神經節苷脂沉積症治療市場預計在2026年達到1.942億美元，預計2033年將達到16.589億美元。預計從2026年到2033年，其複合年成長率將達到36.7%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	1.942億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	36.70%	16.589億美元

GM1神經節苷脂沉積症是一種進行性性神經系統遺傳性疾病，主要由一種名為BETA-半乳糖苷酶（GLB1）的關鍵酵素缺乏所引起。當GLB1缺乏時，一種名為GM1神經節苷脂的脂質會在腦細胞和神經細胞中累積。 GM1神經節苷脂沉積症是50種溶小體儲積症之一。目前，GM1神經節苷脂沉積症尚無有效的治療方法或治癒手段。

市場動態

各大公司正致力於建立策略夥伴關係以擴大市場佔有率。例如，2017年5月，Lysogene與病毒基因和細胞療法生產商Brammer Bio達成策略性生產協議。該協議預計將使Brammer Bio能夠生產LYS-GM101，這是一種基於AAVrh10的基因療法，用於治療GM1神經節苷脂沉積症。

本報告的主要特點

本報告對全球 GM1 神經節苷脂病治療市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本報告根據公司概況、產品系列、主要亮點、財務績效和策略等各種參數，介紹了全球 GM1 神經節苷脂病治療市場主要公司的概況。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球 GM1 神經節苷脂病治療市場》報告面向該行業的眾多相關人員，包括投資者、產品開發商和製造商、經銷商、醫療保健和研究機構、新參與企業和金融分析師。
相關人員可以透過分析全球 GM1 神經節苷脂病治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- 波灣合作理事會（GCC）國家
- 以色列
- 其他中東國家
非洲
- 中非
- 南部非洲
- 北非

第7章競爭情勢

公司簡介
- Axovant Gene Therapies Ltd.
- Passage Bio
- Lysogene

簡介目錄

Product Code: CMI4270

Gm1 Gangliosidosis Treatment Market is estimated to be valued at USD 194.2 Mn in 2026 and is expected to reach USD 1,658.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 36.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 194.2 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	36.70%	2033 Value Projection:	USD 1,658.9 Mn

GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study

This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (USD Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026-2033)
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global GM1 gangliosidosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Gm1 Gangliosidosis Treatment Market Segmentation

By Product Type
- LYS-GM101
- PBGM01
- AXO-AAV-GM1
By Disease Type
- Type 1 GM1 Gangliosidosis
- Type 2 GM1 Gangliosidosis
- Type 3 GM1 Gangliosidosis
Global Gm1 Gangliosidosis Treatment Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Competitive Landscape
Company Profiles
- Axovant Gene Therapies Ltd.
- Passage Bio
- Lysogene

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Key Development
Epidemiology
Primary Research Insights
- Patient Insights
- Physician Insights
- Manufacturer Insights

4. Global GM1 Glangliosidosis Treatment Market, By Product Type, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
LYS-GM101
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
PBGM01
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
AXO-AAV-GM1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

5. Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Type 1 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Type 2 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
Type 3 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)

6. Global GM1 Glangliosidosis Treatment Market, By Region, 2021-2033 (USD Mn)

Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Countries, 2022-2033
North America
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Product Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Disease Type, 2021-2033 (USD Mn)
- Market Size and Forecast, By Country, 2021-2033 (USD Mn)
  - Central Africa
  - South Africa
  - North Africa

7. Competitive Landscape

Company Profiles
- Axovant Gene Therapies Ltd.
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Passage Bio
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Lysogene
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies